Effects of Delta-9-THC and Iomazenil in Healthy Humans
Conditions
Mental Disorders | Psychotic Disorders | Schizophrenia
Trial Phase
Phase 1
Trial Purpose and Description
Trial Purpose
The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.
Participation Guidelines
- Age:
- 18 Years - 55 Years
- Gender:
- Male
Eligibility Criteria
Inclusion Criteria:
- Exposed to cannabis at least once in their lifetime
Exclusion Criteria:
- Cannabis na6ve
- History of hearing deficit
- Sponsor:
- Yale University
- Dates:
- February 2009
- Last Updated:
- June 26, 2012
- Study HIC#:
- 0901004662
Clinicaltrials.gov ID: NCT00982982


